1. Home
  2. STEW vs AAPG Comparison

STEW vs AAPG Comparison

Compare STEW & AAPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SRH Total Return Fund Inc.

STEW

SRH Total Return Fund Inc.

HOLD

Current Price

$18.24

Market Cap

1.7B

Sector

Finance

ML Signal

HOLD

AAPG

Ascentage Pharma Group International American Depository Shares

HOLD

Current Price

$20.18

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
STEW
AAPG
Founded
N/A
2009
Country
United States
China
Employees
N/A
767
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
2.0B
IPO Year
1996
N/A

Fundamental Metrics

Financial Performance
Metric
STEW
AAPG
Price
$18.24
$20.18
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$48.40
AVG Volume (30 Days)
83.9K
16.2K
Earning Date
01-01-0001
05-20-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$290.34
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$16.55
$16.36
52 Week High
$18.67
$48.45

Technical Indicators

Market Signals
Indicator
STEW
AAPG
Relative Strength Index (RSI) 67.76 48.53
Support Level $18.31 $18.56
Resistance Level $18.54 $27.98
Average True Range (ATR) 0.20 0.67
MACD 0.02 0.23
Stochastic Oscillator 86.49 46.46

Price Performance

Historical Comparison
STEW
AAPG

About STEW SRH Total Return Fund Inc.

SRH Total Return Fund, Inc. is a non-diversified closed-end management investment company. The company's investment objective is to seek total returns. Its fund utilizes a bottom-up, value-driven investment process to identify securities of good quality businesses trading below estimated intrinsic value. The Funds are available as an actively-managed closed-end fund, an actively managed ETF and a passively-managed ETF.

About AAPG Ascentage Pharma Group International American Depository Shares

Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies and currently has seven drug candidates in pipeline under research. The company's geographical segments include the United States and Mainland China.

Share on Social Networks: